Rasmus is a globally recognised expert on scientific information and knowledge dissemination. He spent his earlier career as a Fortune500 strategist. Rasmus is a strong believer in the power of accurate information and new ideas - he founded his first, short lived, newspaper at the age of 13 - a passion that drove him to found Airfinity. As CEO of Airfinity he is often quoted in leading media companies such as Financial times, Bloomberg and CNN. He is a board member of the newspaper group, Information.dk. Rasmus holds a B.Sc. in Political Science, a MPA from Harvard University and is a recipient of the Crown Prince Frederic award for excellent scholarship. He lives in London.
Abid is a senior financial expert, known for driving radical growth, and building the financial infrastructure of a multi-million enterprise. He has considerable experience of structuring companies on their scaling up journey, and designing efficient reporting & decision making systems while supporting commercial operations. Prior to joining Airfinity as Chief Financial Officer (CFO), Abid was CFO of property tech platform Plentific, a co-founder of an ecommerce platform which he listed on the London Stock and an M&A assistant director at Ernst & Young (EY). Abid also holds a BSc in Applied Economics, and is ACA (ICAEW) qualified accountant.
Tor is an experienced business leader with a demonstrated history of significant top line growth within the business information industry, as well as strategic client development and people leadership. Tor holds a BSC Hons degree in Applied Science from the University of Exeter, an MSc in Marketing and Product Management from Cranfield and has also completed an AMP at INSEAD Business School. Prior to joining Airfinity as Chief Revenue Officer, Tor was a Senior Vice President of Global Sales at Clarivate Analytics and Vice President, Global Sales of Upstream Energy at IHS Markit.
Claus Henrik Johansen is a highly experienced Life Science investor. He was with Danske Bank Asset Management as a Senior Portfolio Manager since 2002 and has more than 17 years of experience investing within the Life Science industry. Claus participates in many global investor conferences and medical conferences in both US and Europe, and holds solid experience within both the healthcare and pharmaceutical value chain.
Henrik Sillesen is Medical Director of Clinical Science at the Novo Nordisk Foundation and Professor of Vascular Disease at the University of Copenhagen. Henrik is an internationally, well recognised KOL in cardiovascular disease, has published extensively, has lectured in 35 countries and led dept. of vascular of vascular surgery at Rigshospitalet for 23 years. Henrik is a member of Guideline Committees for European Society for Vascular Surgery and European Society for Cardiology. Henrik served as President of the European Society for Vascular Surgery (ESVS) from 2018-9, served as secretary general for ESVS in 2004-9, was the president of the Danish Heart Foundation across 2004-8, the President of the World Federation of Vascular Specialties 2009-10 and the President of the Danish Vascular Society from 2002-4. Henrik has worked closely with Danish and European Health Authorities and has collaborated with and advised many major Pharma and Medtech companies.
Arsalan is a former Victor Dahdaleh Fellow in the Department of Medicine at the University of Cambridge. He has an MSc from the University of Oxford in Molecular Oncology and a PhD in Cell Biology from Jesus College at the University of Cambridge. Arsalan has published several high-impact factor publications including in Nature and Small, with his most recent first author publication receiving attention in 110+ news outlets. He is also co-founder of two start-ups, SAANethical and PolicyBench.
Bhaskar is the lead analyst within cardio-metabolics. He is a Rhodes Scholar and a former Novo Nordisk STAR Research Fellow at the Department of Organic Chemistry and the Wellcome Centre for Human Genetics at the University of Oxford. Bhaskar has over 10 years' experience in developing drugs to study the biology of diabetes, cardiovascular disease and the epigenetic response. His research has resulted in departmental and university-level awards as well as publications in high impact factor journals. He holds a PhD from Oxford University.
Caroline heads up the Covid-19 team with a degree in Pharmacology from the University of Cambridge. Caroline has multiple years of experience in consulting in the pharmaceutical area and has worked with many of the industry's largest companies. At Airfinity, she has played a key role in building up the firm’s Covid-19 coverage and advises governments, investment funds and multi-nationals.
Jyothi has over 13 years of software development experience in designing, developing and implementing various applications including backend systems, data engineering, text/data mining and NLP pipelines in bioinformatics, academics and internet security. She previously worked for 9 years at the European Bioinformatics Institute in the UK. She holds an MCA (Master of Computer Applications) degree from India and enjoys developing NLP models in her spare time.
Louis has more than 8 years’ experience and wide-ranging exposure to the life science sector. He previously held a senior role at IQVIA where he managed and delivered challenging, multifaceted projects for a variety of healthcare clients, ranging in topics from therapy area deep dives, forecasting, product lifecycle management and competitor benchmarking. He completed his PhD in Structural Biology at Imperial College London and UCL, in collaboration with AstraZeneca.
Louise leads the COVID-19 vaccine and variants teams. She holds a PhD in Biochemical Immunology from The Francis Crick Institute and 1st class honours degree in Biochemistry from UCL. During her studies she developed her coding skills, in R, SQL and Python to allow her to interrogate and analyse large datasets, and science communication skills, giving talks at large fundraising events for charities such as CRUK. Louise uses these skills to understand the vaccine and variant landscape to translate data into actionable insights for international companies, governments and NGOs.
Matt works in the infectious diseases team on forecasting and predictive models. He holds a PhD from the University of Cambridge, where he researched cellular interactions and bioactivity of medical materials. During his doctoral studies, Matt presented his research at international conferences, published a peer-reviewed paper and also patented the technology that he developed. Prior to his PhD, Matt achieved a 1st Class Honours Degree in Biotechnology and Bioengineering.
Simon has substantial experience in data and systems architecture, gained through working with small, medium, and large organisations as a data scientist and consulting engineer in diverse fields, including the telecommunications, nuclear, and space industries. He holds an MSc (Dist.) in Modern Communication Technologies with Business Management from the University of Sussex, an NZCE in Electronics Engineering, is a former military officer and member of the IET and IEEE. Simon has had one conference paper published as first author, in the field of medical imaging.